Almirall, S.A.
6 products tracked · names used in filings: Almirall, S.A.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Ebglyss lebrikizumab | Authorised | 2023-11-16 |
| 🇪🇺 | Klisyri tirbanibulin | Authorised | 2021-07-16 |
| 🇪🇺 | Ilumetri tildrakizumab | Authorised | 2018-09-17 |
| 🇪🇺 | Skilarence dimethyl fumarate | Authorised | 2017-06-23 |
| 🇪🇺 | Vaniqa eflornithine | Authorised | 2001-03-19 |
| 🇪🇺 | Prometax rivastigmine | Authorised | 1998-12-04 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.